Hepatic Resection for Colorectal Liver Metastases following Panitumumab(Vectibix) with Chemotherapy Cohort study

Trial Profile

Hepatic Resection for Colorectal Liver Metastases following Panitumumab(Vectibix) with Chemotherapy Cohort study

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2015

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2015 Status changed from recruiting to discontinued, according to University Hospital Medical Information Network - Japan record.
    • 04 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top